JP6113185B2 - テロメラーゼ基質およびテロメア長作用因子としてのグアニンアナログ - Google Patents

テロメラーゼ基質およびテロメア長作用因子としてのグアニンアナログ Download PDF

Info

Publication number
JP6113185B2
JP6113185B2 JP2014548785A JP2014548785A JP6113185B2 JP 6113185 B2 JP6113185 B2 JP 6113185B2 JP 2014548785 A JP2014548785 A JP 2014548785A JP 2014548785 A JP2014548785 A JP 2014548785A JP 6113185 B2 JP6113185 B2 JP 6113185B2
Authority
JP
Japan
Prior art keywords
alkyl
substituted
hydrogen
compound
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014548785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502979A (ja
JP2015502979A5 (https=
Inventor
セルゲイ エム． グリャズノフ，
セルゲイ エム． グリャズノフ，
ロナルド エー． プルザン，
ロナルド エー． プルザン，
クリスティナ ポングラツ，
クリスティナ ポングラツ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of JP2015502979A publication Critical patent/JP2015502979A/ja
Publication of JP2015502979A5 publication Critical patent/JP2015502979A5/ja
Application granted granted Critical
Publication of JP6113185B2 publication Critical patent/JP6113185B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014548785A 2011-12-22 2012-12-21 テロメラーゼ基質およびテロメア長作用因子としてのグアニンアナログ Active JP6113185B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161579575P 2011-12-22 2011-12-22
US61/579,575 2011-12-22
PCT/US2012/000586 WO2013095684A1 (en) 2011-12-22 2012-12-21 Guanine analogs as telomerase substrates and telomere length affectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016251548A Division JP2017081961A (ja) 2011-12-22 2016-12-26 テロメラーゼ基質およびテロメア長作用因子としてのグアニンアナログ

Publications (3)

Publication Number Publication Date
JP2015502979A JP2015502979A (ja) 2015-01-29
JP2015502979A5 JP2015502979A5 (https=) 2016-02-18
JP6113185B2 true JP6113185B2 (ja) 2017-04-12

Family

ID=48669322

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014548785A Active JP6113185B2 (ja) 2011-12-22 2012-12-21 テロメラーゼ基質およびテロメア長作用因子としてのグアニンアナログ
JP2016251548A Pending JP2017081961A (ja) 2011-12-22 2016-12-26 テロメラーゼ基質およびテロメア長作用因子としてのグアニンアナログ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016251548A Pending JP2017081961A (ja) 2011-12-22 2016-12-26 テロメラーゼ基質およびテロメア長作用因子としてのグアニンアナログ

Country Status (7)

Country Link
US (5) US9593137B2 (https=)
EP (2) EP3578563B1 (https=)
JP (2) JP6113185B2 (https=)
CA (1) CA2857490C (https=)
DK (2) DK3578563T3 (https=)
ES (2) ES2874774T3 (https=)
WO (1) WO2013095684A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874774T3 (es) * 2011-12-22 2021-11-05 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
KR102163611B1 (ko) 2015-08-10 2020-10-08 머크 샤프 앤드 돔 코포레이션 항바이러스 베타-아미노산 에스테르 포스포디아미드 화합물
EP3386512B1 (en) 2015-12-10 2023-11-22 Merck Sharp & Dohme LLC Antiviral phosphodiamide prodrugs of tenofovir
EP3390413B1 (en) 2015-12-15 2020-08-19 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
US10736908B2 (en) 2016-10-26 2020-08-11 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
US11123355B2 (en) 2016-12-22 2021-09-21 Idenix Pharmaceuticals Llc Antiviral benzyl-amine phosphodiamide compounds
TWI820984B (zh) 2017-01-31 2023-11-01 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
KR102867725B1 (ko) 2017-07-28 2025-10-13 제론 코포레이션 골수형성이상 증후군의 치료 방법
US11826375B2 (en) 2018-07-19 2023-11-28 Merck Sharp & Dohme Llc Phosphinic amide prodrugs of tenofovir
UA130012C2 (uk) 2018-11-29 2025-10-15 Джерон Корпорейшн Спосіб лікування мієлодиспластичного синдрому
CN111205326B (zh) * 2020-02-13 2020-09-22 南京道尔医药科技有限公司 一种绿色环保的泰诺福韦制备方法
EP4463151A4 (en) 2022-01-19 2025-10-01 Univ Northwestern Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
IL84477A (en) 1986-11-18 1995-12-08 Bristol Myers Squibb Co History of Phosphonomethoxyalkylene Purinopyrimidine and Pharmaceutical Preparations Containing Them
AU8092587A (en) 1986-11-18 1988-05-19 Bristol-Myers Squibb Company Synthesis of purin-9-ylalkylenoxymethyl phosphonic acids
EP0405748A1 (en) 1989-05-30 1991-01-02 Beecham Group p.l.c. Phosphonoderivative of purine with antiviral activity
EP0452935B1 (en) 1990-04-20 1995-06-21 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
CZ285420B6 (cs) 1990-04-24 1999-08-11 Ústav Organické Chemie A Biochemie Avčr N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
CS387190A3 (en) 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2r)-2-/di(2-propyl)phosphonylmethoxy/-3-p-toluenesulfonyloxy -1- trimethylacetoxypropane and process for preparing thereof
FI930552A7 (fi) 1990-08-10 1993-02-22 Rega Stichting Uusi menetelmä nukleotidien valmistamiseksi
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
GB9020932D0 (en) 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
GB9026164D0 (en) 1990-12-01 1991-01-16 Beecham Group Plc Pharmaceuticals
CZ284678B6 (cs) 1991-05-20 1999-01-13 Ústav Organické Chemie A Biochemie Avčr Di(2-propyl)estery 1-fluor-2-fosfonomethoxy-3-p -toluensulfonyloxypropanů, způsob jejich přípravy a použití
EP0531597A1 (en) 1991-09-12 1993-03-17 Merrell Dow Pharmaceuticals Inc. Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine
CZ287745B6 (cs) 1991-10-11 2001-01-17 Ústav organické chemie a biochemie AV ČR Acyklické fosfonomethoxyalkylsubstituované alkenylové a alkinylové deriváty purinu a pyrimidinu
GB9205917D0 (en) 1992-03-18 1992-04-29 Smithkline Beecham Plc Pharmaceuticals
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
US5532225A (en) 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5817647A (en) 1993-04-01 1998-10-06 Merrell Pharmaceuticals Inc. Unsaturated acetylene phosphonate derivatives of purines
EP0618214A1 (en) 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
AU691527B2 (en) 1993-09-17 1998-05-21 Gilead Sciences, Inc. Nucleotide analogs
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
WO1995026734A1 (en) 1994-04-04 1995-10-12 Freeman William R Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
IT1270008B (it) 1994-09-23 1997-04-16 Ist Superiore Sanita Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids
JP3906488B2 (ja) 1995-02-21 2007-04-18 味の素株式会社 プリン誘導体の製造方法
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
CA2224710A1 (en) 1995-06-15 1997-01-03 Naoko Inoue Phosphonate nucleotide derivatives
CA2195262C (en) 1996-01-18 2005-08-09 Masaru Ubasawa Phosphonate nucleotide compounds
US5874577A (en) 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US6194398B1 (en) 1996-08-13 2001-02-27 Mitsubishi Chemical Corporation Phosphonate nucleotide compound
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
US6252061B1 (en) 1998-03-23 2001-06-26 Reliable Biopharmaceutical, Inc. Process for the production of 2-halo-6-aminopurine derivatives
SI20022A (sl) 1998-07-29 2000-02-29 Kemijski inštitut Alkilno substituirani purinovi derivati in njihova priprava
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6995145B1 (en) 1999-06-04 2006-02-07 Au Jessie L-S Methods and compositions for modulating drug activity through telomere damage
CN1317291C (zh) 1999-09-10 2007-05-23 杰龙公司 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用
DE60011637T2 (de) 1999-09-24 2004-11-11 Shire Biochem Inc., Laval Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen
DE60038038T2 (de) 1999-12-03 2009-02-12 The Regents of The University of California at San Diego, La Jolla Phosphonatverbindungen
AU2439701A (en) 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Novel heterocycles
ATE322494T1 (de) 2000-01-07 2006-04-15 Universitaire Instelling Antwe Purin derivate, ihre herstellung und verwendung
WO2001064693A1 (fr) 2000-02-29 2001-09-07 Mitsubishi Pharma Corporation Compose de nucleotide de phosphonate
CZ304734B6 (cs) 2000-07-21 2014-09-10 Gilead Sciences, Inc. Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
KR20020097384A (ko) 2001-06-20 2002-12-31 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 기존의 약제에 내성변이를 가지는 바이러스에 유효한 약제
WO2003028737A1 (en) 2001-08-30 2003-04-10 Mitsubishi Pharma Corporation Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon
EA200400690A1 (ru) 2001-11-14 2005-06-30 Байокрист Фармасьютикалз, Инк. Нуклеозиды, их препараты и их применение в качестве ингибиторов вирусных рнк-полимераз
US6858393B1 (en) 2002-03-13 2005-02-22 Stratagene California Chain terminators for DNA synthesis
WO2003087302A2 (en) 2002-04-12 2003-10-23 Stratagene Dual-labeled nucleotides
NZ536328A (en) 2002-05-13 2007-11-30 Metabasis Therapeutics Inc Novel phosphonic acid based prodrugs of PMEA and its analogues
AU2003242428A1 (en) 2002-05-24 2003-12-12 Mitsubishi Pharma Corporation Drugs improved in tissue selectivity
US20040157793A1 (en) 2002-11-12 2004-08-12 Stuyver Lieven J. Modified nucleosides as antiviral agents
MXPA05007016A (es) 2003-01-14 2005-09-12 Gilead Sciences Inc Composiciones y metodos para terapia antiviral de combinacion.
WO2004106350A1 (en) 2003-05-14 2004-12-09 Biocryst Pharmaceutical, Inc. Nucleoside analogs as viral polymerase inhibitors
DE602004031115D1 (de) 2003-06-16 2011-03-03 Acad Of Science Czech Republic Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga
AU2004260789B2 (en) 2003-07-30 2011-06-30 Gilead Sciences, Inc. Nucleobase phosphonate analogs for antiviral treatment
US20070185007A1 (en) 2003-09-19 2007-08-09 Haolun Jin Aza-quinolinol phosphonate integrase inhibitor compounds
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
US7553825B2 (en) 2003-12-30 2009-06-30 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US8063209B2 (en) 2004-07-02 2011-11-22 Tsrl, Inc. Phosphonyl ester conjugates as prodrugs
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
ITFI20040173A1 (it) 2004-08-03 2004-11-03 Protera S R L Profarmaci attivati da dna polimerasi dipendenti da rna
WO2006066074A2 (en) * 2004-12-16 2006-06-22 The Regents Of The University Of California Lung-targeted drugs
CA2602562C (en) 2005-03-25 2015-07-07 Alt Solutions, Inc. Modulation of telomere length in telomerase positive cells and cancer therapy
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
ES2261072B1 (es) 2005-04-06 2007-12-16 Consejo Superior Investig. Cientificas Fosforotioatos derivados de analogos a nucleosido para terapia antirretroviral.
WO2006114064A2 (en) 2005-04-25 2006-11-02 Institute Of Organic Chemistry And Biochemistry Ofthe Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
CN101588805A (zh) 2005-05-18 2009-11-25 Alt解决方案公司 为预防和治疗癌症对癌细胞中端粒长度的药理学调节
WO2007002912A2 (en) 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
WO2007014491A1 (fr) 2005-08-03 2007-02-08 Beijing Fu Kang Ren Bio-Pharm Tech.Co.Ltd. Phosphonates de nucléotides acycliques et leur utilisation dans des agents antiviraux
WO2007106450A2 (en) 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
ES2600792T3 (es) 2006-05-03 2017-02-10 Chimerix, Inc. Alcoxialquilésteres metabólicamente estables de fosfonatos, fosfonatos nucleosídicos y fosfatos nucleosídicos antivirales o antiproliferativos
WO2008001953A1 (en) 2006-06-30 2008-01-03 Panasonic Corporation Node discovery method for providing optimal path preserving location privacy
EP2038290B1 (en) 2006-07-07 2013-09-04 Gilead Sciences, Inc. Modulators of toll-like receptor 7
FR2908133B1 (fr) 2006-11-08 2012-12-14 Centre Nat Rech Scient Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux
WO2008133966A1 (en) 2007-04-27 2008-11-06 Chimerix, Inc. Methods of reducing nephrotoxicity in subjects administered with nucleoside
WO2008134578A2 (en) 2007-04-28 2008-11-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Synthesis of optically active radio-labeled reverse transcriptase inhibitors
GB0709408D0 (en) 2007-05-16 2007-06-27 Katholleke Universiteit Leuven Anti-col herpes virus compounds
EP2254582B1 (en) 2008-01-25 2016-01-20 Chimerix, Inc. Methods of treating viral infections
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
WO2009115927A2 (en) 2008-03-18 2009-09-24 Institut De Recherches Cliniques De Montreal Nucleotide analogues with quaternary carbon stereogenic centers and methods of use
US20100081713A1 (en) 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
US20110059921A1 (en) 2008-03-27 2011-03-10 Ektar Therapeutics Oligomer-Nitrogenous Base Conjugates
CA2721586A1 (en) 2008-04-15 2009-10-22 Mallinckrodt Inc. Compositions containing antiviral compounds and methods of using the same
CA2734778C (en) 2008-08-21 2017-06-06 Third Rock Ventures Device for drug evaluation and local treatment
JP2012517443A (ja) 2009-02-06 2012-08-02 アールエフエス ファーマ，エルエルシー 癌及びウイルス感染の治療のためのプリンヌクレオシド一リン酸プロドラッグ
WO2011011710A1 (en) 2009-07-24 2011-01-27 Chimerix, Inc. Methods of treating viral infections
WO2011017253A1 (en) 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
WO2011053812A1 (en) 2009-10-30 2011-05-05 Chimerix, Inc. Methods of treating viral associated diseases
WO2011071849A2 (en) 2009-12-07 2011-06-16 University Of Georgia Research Foundation, Inc. Pyridinone hydroxycyclopentyl carboxamides: hiv integrase inhibitors with therapeutic applications
CN102093422B (zh) 2009-12-10 2015-02-25 中国人民解放军军事医学科学院毒物药物研究所 无环核苷膦酸酯衍生物及其医药用途
CA2794631A1 (en) 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
EP2558466A4 (en) 2010-04-14 2013-11-13 Univ California PHOSPHONATES WITH REDUCED TOXICITY FOR THE TREATMENT OF VIRUS INFECTIONS
WO2011133963A2 (en) 2010-04-23 2011-10-27 University Of Southern California Tyrosine-based prodrugs of antiviral agents
US9029344B2 (en) 2010-06-18 2015-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Linked purine pterin HPPK inhibitors useful as antibacterial agents
CZ201126A3 (cs) * 2011-01-18 2012-05-09 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Zpusob výroby substituovaných diamidu fosfonových kyselin
ES2874774T3 (es) * 2011-12-22 2021-11-05 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros

Also Published As

Publication number Publication date
US20200283461A1 (en) 2020-09-10
JP2017081961A (ja) 2017-05-18
ES2874774T3 (es) 2021-11-05
JP2015502979A (ja) 2015-01-29
DK3578563T3 (da) 2021-05-31
HK1205515A1 (en) 2015-12-18
DK2794624T3 (da) 2019-07-22
US10562926B2 (en) 2020-02-18
US20170233419A1 (en) 2017-08-17
CA2857490C (en) 2020-03-31
US11279720B2 (en) 2022-03-22
EP2794624A1 (en) 2014-10-29
ES2734495T3 (es) 2019-12-10
WO2013095684A1 (en) 2013-06-27
US12398162B2 (en) 2025-08-26
US9593137B2 (en) 2017-03-14
US20190106447A1 (en) 2019-04-11
EP3578563A1 (en) 2019-12-11
US20220306660A1 (en) 2022-09-29
US10035814B2 (en) 2018-07-31
EP2794624A4 (en) 2015-04-29
EP3578563B1 (en) 2021-04-14
CA2857490A1 (en) 2013-06-27
US20150299232A1 (en) 2015-10-22
EP2794624B1 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
JP6113185B2 (ja) テロメラーゼ基質およびテロメア長作用因子としてのグアニンアナログ
US11286265B2 (en) Macrocyclic compounds for treating disease
CA2998189C (en) Methods for treating arenaviridae and coronaviridae virus infections
KR102042290B1 (ko) 글루타미나제의 헤테로사이클릭 억제제
JP7121660B2 (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
JP6538656B2 (ja) ５’−ヌクレオチダーゼ阻害剤およびその治療的使用
EP3212651B1 (en) Administration of ubiquitin-activating enzyme inhibitor and radiation
BR112020002736A2 (pt) inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
HU228985B1 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
TW201201815A (en) 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
JP2018529742A (ja) Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法
JP6794258B2 (ja) オリゴヌクレオチドについてのホスホロジアミデート骨格結合
HK40018795B (en) Guanine analogs as telomerase substrates and telomere length affectors
HK40018795A (en) Guanine analogs as telomerase substrates and telomere length affectors
HK1205515B (en) Guanine analogs as telomerase substrates and telomere length affectors
WO2016123626A1 (en) Combination therapy for treating cancer
CN117126162A (zh) 多取代杂环类化合物及其制备方法和应用
WO2026006342A1 (en) Direct-binding dual inhibitors of hypoxia-inducible factor 1 (hif-1) and hif-2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170314

R150 Certificate of patent or registration of utility model

Ref document number: 6113185

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250